NASDAQ:KNTE Kinnate Biopharma (KNTE) Stock Forecast, Price & News $3.71 -0.02 (-0.54%) (As of 02:27 PM ET) Add Compare Share Share Today's Range$3.57▼$3.8750-Day Range$2.33▼$6.8452-Week Range$2.32▼$15.86Volume128,664 shsAverage Volume294,159 shsMarket Capitalization$172.77 millionP/E RatioN/ADividend YieldN/APrice Target$17.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Kinnate Biopharma MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside365.0% Upside$17.25 Price TargetShort InterestBearish8.75% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.08Based on 4 Articles This WeekInsider TradingAcquiring Shares$9.07 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.03) to ($2.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.86 out of 5 starsMedical Sector43rd out of 1,009 stocksPharmaceutical Preparations Industry16th out of 494 stocks 4.4 Analyst's Opinion Consensus RatingKinnate Biopharma has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.25, Kinnate Biopharma has a forecasted upside of 365.0% from its current price of $3.71.Amount of Analyst CoverageKinnate Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.75% of the float of Kinnate Biopharma has been sold short.Short Interest Ratio / Days to CoverKinnate Biopharma has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Kinnate Biopharma has recently increased by 10.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKinnate Biopharma does not currently pay a dividend.Dividend GrowthKinnate Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKinnate Biopharma has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Kinnate Biopharma is -0.81. Previous Next 2.3 News and Social Media Coverage News SentimentKinnate Biopharma has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kinnate Biopharma this week, compared to 2 articles on an average week.Search Interest45 people have searched for KNTE on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Kinnate Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kinnate Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,074,491.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders37.90% of the stock of Kinnate Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.68% of the stock of Kinnate Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kinnate Biopharma are expected to grow in the coming year, from ($3.03) to ($2.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kinnate Biopharma is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kinnate Biopharma is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKinnate Biopharma has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kinnate Biopharma (NASDAQ:KNTE) StockKinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.Read More Receive KNTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address KNTE Stock News HeadlinesMay 30, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Hold Rating on Kinnate Biopharma (KNTE)May 24, 2023 | americanbankingnews.comKinnate Biopharma Inc. (NASDAQ:KNTE) to Post Q2 2023 Earnings of ($0.78) Per Share, HC Wainwright ForecastsMay 30, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 22, 2023 | americanbankingnews.comKinnate Biopharma (NASDAQ:KNTE) Earns Maintains Rating from 500.comMay 21, 2023 | americanbankingnews.comHC Wainwright Cuts Kinnate Biopharma (NASDAQ:KNTE) Price Target to $24.00May 18, 2023 | markets.businessinsider.comKinnate Biopharma in Focus: Analyst's Adjusted Price Target and the Potential of KIN-3248May 18, 2023 | markets.businessinsider.comExpert Ratings for Kinnate BiopharmaMay 18, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Kinnate Biopharma (KNTE)May 30, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.May 14, 2023 | americanbankingnews.comKinnate Biopharma (NASDAQ:KNTE) Releases Earnings Results, Meets ExpectationsMay 12, 2023 | msn.comStifel Maintains Kinnate Biopharma (KNTE) Hold RecommendationMay 12, 2023 | msn.comWedbush Reiterates Kinnate Biopharma (KNTE) Outperform RecommendationMay 12, 2023 | marketwatch.com8-K: Kinnate Biopharma Inc.May 12, 2023 | markets.businessinsider.comWedbush Sticks to Their Buy Rating for Kinnate Biopharma (KNTE)May 12, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Buy Rating on Kinnate Biopharma (KNTE)May 11, 2023 | finance.yahoo.comKinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate UpdatesMay 11, 2023 | americanbankingnews.comKinnate Biopharma Inc. (NASDAQ:KNTE) Director James B. Tananbaum Acquires 1,780,000 SharesMay 10, 2023 | finance.yahoo.comWhy Earnings Season Could Be Great for Kinnate Biopharma (KNTE)May 10, 2023 | americanbankingnews.comOrbimed Advisors Llc Acquires 479,909 Shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) StockMay 7, 2023 | americanbankingnews.comMustang Bio (NASDAQ:MBIO) versus Kinnate Biopharma (NASDAQ:KNTE) Critical ContrastMay 5, 2023 | americanbankingnews.comKinnate Biopharma Inc. (NASDAQ:KNTE) Director Acquires $894,409.95 in StockMay 5, 2023 | americanbankingnews.comKinnate Biopharma Inc. (NASDAQ:KNTE) Director Carl L. Gordon Purchases 716,157 SharesMay 4, 2023 | msn.comOrbimed Boosts Kinnate Biopharma Stake With 1.4 Million Share PurchaseApril 22, 2023 | americanbankingnews.comKinnate Biopharma (NASDAQ:KNTE) Price Target Lowered to $25.00 at HC WainwrightApril 22, 2023 | americanbankingnews.comKinnate Biopharma (NASDAQ:KNTE) Price Target Cut to $26.00April 22, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Kinnate Biopharma Inc. Decreased by Analyst (NASDAQ:KNTE)April 22, 2023 | americanbankingnews.comQ1 2023 Earnings Forecast for Kinnate Biopharma Inc. (NASDAQ:KNTE) Issued By WedbushSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KNTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address KNTE Company Calendar Last Earnings5/11/2023Today5/30/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KNTE CUSIPN/A CIK1797768 Webwww.kinnate.com Phone858-299-4699FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.25 High Stock Price Forecast$26.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+372.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.53% Return on Assets-42.59% Debt Debt-to-Equity RatioN/A Current Ratio11.31 Quick Ratio11.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.06 per share Price / Book0.72Miscellaneous Outstanding Shares46,570,000Free Float28,922,000Market Cap$169.98 million OptionableNot Optionable Beta0.23 Key ExecutivesMr. Nima Farzan M.B.A. (Age 47)Pres, CEO & Director Comp: $778.92kMs. Neha Krishnamohan (Age 36)CFO, Principal Accounting Officer and Exec. VP of Corp. Devel. Comp: $459.52kMr. Mark A. Meltz (Age 49)COO, Gen. Counsel, Treasurer & Sec. Comp: $586.49kMs. Priyanka ShahVP of Investor Relations & CommunicationsMs. Barbara WarrenVP of People & CultureDr. Richard Thomas Williams MBBS (Age 54)Ph.D., Chief Medical Officer Dr. Robert Kania Ph.D.Sr. VP of Drug DiscoveryMr. Jason Hampson M.D.VP and Head of Regulatory Affairs & QualityMore ExecutivesKey CompetitorsInflaRxNASDAQ:IFRXZevra TherapeuticsNASDAQ:ZVRAADC TherapeuticsNYSE:ADCTCara TherapeuticsNASDAQ:CARAImmutepNASDAQ:IMMPView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 5,962 shares on 5/18/2023Ownership: 0.051%State Street CorpBought 3,199 shares on 5/16/2023Ownership: 1.001%Geode Capital Management LLCBought 13,775 shares on 5/16/2023Ownership: 0.956%Jane Street Group LLCBought 3,842 shares on 5/16/2023Ownership: 0.035%Susquehanna International Group LLPBought 11,800 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions KNTE Stock - Frequently Asked Questions Should I buy or sell Kinnate Biopharma stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KNTE shares. View KNTE analyst ratings or view top-rated stocks. What is Kinnate Biopharma's stock price forecast for 2023? 4 brokers have issued 12-month price objectives for Kinnate Biopharma's stock. Their KNTE share price forecasts range from $5.00 to $26.00. On average, they predict the company's stock price to reach $17.25 in the next twelve months. This suggests a possible upside of 372.6% from the stock's current price. View analysts price targets for KNTE or view top-rated stocks among Wall Street analysts. How have KNTE shares performed in 2023? Kinnate Biopharma's stock was trading at $6.10 on January 1st, 2023. Since then, KNTE shares have decreased by 40.2% and is now trading at $3.65. View the best growth stocks for 2023 here. When is Kinnate Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our KNTE earnings forecast. How were Kinnate Biopharma's earnings last quarter? Kinnate Biopharma Inc. (NASDAQ:KNTE) posted its quarterly earnings data on Thursday, May, 11th. The company reported ($0.73) EPS for the quarter, hitting the consensus estimate of ($0.73). What ETF holds Kinnate Biopharma's stock ? BlackRock Future Health ETF holds 553 shares of KNTE stock, representing 0.02% of its portfolio. When did Kinnate Biopharma IPO? (KNTE) raised $170 million in an initial public offering on Thursday, December 3rd 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO. What is Kinnate Biopharma's stock symbol? Kinnate Biopharma trades on the NASDAQ under the ticker symbol "KNTE." Who are Kinnate Biopharma's major shareholders? Kinnate Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.89%), Foresite Capital Management V LLC (4.24%), FMR LLC (3.54%), State Street Corp (1.00%), Geode Capital Management LLC (0.96%) and Charles Schwab Investment Management Inc. (0.30%). Insiders that own company stock include Carl L Gordon, James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams. View institutional ownership trends. How do I buy shares of Kinnate Biopharma? Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kinnate Biopharma's stock price today? One share of KNTE stock can currently be purchased for approximately $3.65. How much money does Kinnate Biopharma make? Kinnate Biopharma (NASDAQ:KNTE) has a market capitalization of $169.98 million. The company earns $-116,270,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis. How can I contact Kinnate Biopharma? The official website for the company is www.kinnate.com. The company can be reached via phone at 858-299-4699 or via email at investors@kinnate.com. This page (NASDAQ:KNTE) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kinnate Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.